v3.26.1
Segments
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segments Segments
The Company manages its business as one reportable operating segment, focused on its core business of advancing innovative precision medicines to improve the lives of patients. The Company has determined its reportable operating segment based on the management approach, which considers the internal organization and reporting used by the Company’s chief operating decision maker ("CODM") to make decisions about allocating resources and assessing the Company’s performance. The Company’s CODM, who is the Chief Executive Officer, uses consolidated single-segment net income (loss) as reported in the condensed consolidated statements of operations to evaluate performance and allocate resources.
The accounting policies of the Company's single operating segment are the same as those described in the summary of significant accounting policies as described in Note 2. As of June 30, 2026, all of the Company's long-lived assets were held in the United States. Expenditures for the addition of long-lived assets are reported on the condensed consolidated statements of
cash flows as purchases of property and equipment.
Total segment net income (loss), which equals consolidated net income (loss) per the condensed consolidated statements of operations was as follows:
Three Months Ended 
 June 30,		Six Months Ended 
 June 30,
2026202520262025
Revenues from external customers/Total segment revenues
$54,978 $856 $78,230 $2,197 
Less:
Salaries, benefits and other payroll expenses, including severance cost(13,205)(9,721)(24,597)(18,907)
Rent and Utilities(1,076)(873)(2,204)(1,805)
Unrealized (appreciation) depreciation in fair value of Warrants— 4,460 — (28,021)
Impairment of Goodwill— (3,907)— (3,907)
Other Segments expenses, net of capitalized inventory costs(20,626)(17,457)(39,287)(30,352)
Net Income (Loss) $20,071 $(26,642)$12,142 $(80,795)
Other segment expenses, net in the table above include external research and development costs, selling, general and administrative expenses and cost of products and services, including third-party commercialization and manufacturing costs, laboratory supplies, consultant costs, legal and professional fees, insurance, and certain other overhead expenses.